International Journal of Radiation Research
نشریه پرتو پژوه
Int J Radiat Res
Basic Sciences
http://ijrr.com
79
journal79
2322-3243
2345-4229
10.61186/ijrr
en
jalali
1402
1
1
gregorian
2023
4
1
21
2
online
1
fulltext
en
Effects of whole-brain radiotherapy, stereotactic ablation radiotherapy, and combined radiotherapy on brain metastases
Radiation Biology
Radiation Biology
تحقيق بديع
Original Research
<div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">To investigate the effects of different radiotherapy regimens on the prognosis of patients with brain metastases. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">Patients with brain metastases undergoing radiotherapy from January 2016 to December 2020 were retrospectively analyzed. The patients were divided into a whole-brain radiotherapy (WBRT) group, stereotactic ablative radiotherapy (SABR) group, and WBRT+SABR group, and overall survival (OS) and progression-free survival (PFS) were analyzed. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">Forty patients were candidates for the analysis, with a median age of 57.5 years and a median follow-up time of 27.4 months. The median OS and PFS were 35.7 and 13.5 months, respectively, and the median radiotherapy dose was 41.7 Gy. The median OS times for patients who received WBRT (n = 12), SABR (n = 21), and WBRT+SABR (n = 7) were 41.8, 70.6, and 56.8 months, respectively (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">p </span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">= 0.7). The median PFS times were 10.2 months, 34.3 months, and 25.9 months, respectively (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">p </span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">= 0.322). Subgroup analysis indicated that the OS times were 25.4 months after WBRT (n = 7), 79.1 months after SABR (n = 11), and 65.9 months after WBRT+SABR (n = 5) among patients with brain metastases from lung cancer (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">p </span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">= 0.028). The patients had PFS times of 7.1, 33.4, and 29.1 months after irradiation with WBRT, SABR, and combination therapy, respectively (</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="font-style:italic"><span style="language:en-US">p </span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">= 0.009). </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">The three different radiotherapy regimens had no significant effects on the prognosis of patients with brain metastases. SBAR was superior to WBRT and WBRT+SABR with respect to the prognosis of patients with brain metastases from lung cancer. The sample size of this retrospective study was small; therefore, larger, prospective studies are needed.</span></span></span></span></span></span></span></span></span></span></div>
Breast cancer, radiotherapy, lymphocytes, chromosomal aberration, bioindicator.
299
303
http://ijrr.com/browse.php?a_code=A-10-1-1042&slc_lang=en&sid=1
Y.
Luo
7900319475328460023776
7900319475328460023776
No
Department of Radiation Oncology, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People’s Republic of China
X.
Huang
7900319475328460023777
7900319475328460023777
No
Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People’s Republic of China
L.
Zhou
zhouliya1988@126.com
7900319475328460023778
7900319475328460023778
Yes
Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People’s Republic of China
J.
Chen
chenjiawei59@126.com
7900319475328460023779
7900319475328460023779
No
Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People’s Republic of China